Nuclear perfusion imaging for functional evaluation of patients with known or suspected coronary artery disease: The future is now

Future Cardiology

Volumn 8, Issue 4, 2012, Pages 603-622

  Mc Ardle, Brian ^a   Ziadi, Maria Cecilia ^a   Ruddy, Terrence D ^a   Beanlands, Rob S ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

coronary artery disease; diagnosis; myocardial perfusion imaging; PET; prognosis; radionuclide; SPECT

Indexed keywords

FLUORODEOXYGLUCOSE; IODOFILTIC ACID I 123; NITROGEN 13; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM 201;

ATHEROGENESIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG HALF LIFE; DRUG METABOLISM; DRUG UPTAKE; ECHOCARDIOGRAPHY; FATTY ACID OXIDATION; FOLLOW UP; FRACTIONAL FLOW RESERVE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; IMAGE QUALITY; META ANALYSIS (TOPIC); MYOCARDIAL PERFUSION IMAGING; NUCLEAR PERFUSION IMAGING; PERCUTANEOUS CORONARY INTERVENTION; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; ENDOTHELIUM, VASCULAR; FLUORODEOXYGLUCOSE F18; HUMANS; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOGRAPHY, INTERVENTIONAL; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TECHNETIUM COMPOUNDS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84864853857     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.40     Document Type: Review

References (102)

1. Gould KL, Johnson NP. Coronary artery disease: Percent stenosis in CAD - A flaw in current practice. Nat. Rev. Cardiol. 7(9), 482-484 (2010).
2. Boden WE, O'Rourke RA, Teo KK et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356(15), 1503-1516 (2007).
3. Frye RL, August P, Brooks MM et al. A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360(24), 2503-2515 (2009).
4. Velazquez EJ, Lee KL, Deja MA et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med. 364(17), 1607-1616 (2011).
5. Tonino PA, De Bruyne B, Pijls NH et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N. Engl. J. Med. 360(3), 213-224 (2009).
6. Shaw LJ, Berman DS, Maron DJ et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE) trial nuclear substudy. Circulation 117(10), 1283-1291 (2008).
7. Hachamovitch R, Rozanski A, Shaw LJ et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur. Heart J. 32(8), 1012-1024 (2011).
8. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107(23), 2900-2907 (2003).
9. D'Egidio G, Nichol G, Williams KA et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: A substudy of the PARR-2 trial. JACC Cardiovasc. Imaging 2(9), 1060-1068 (2009).
10. Ali I, Ruddy TD, Almgrahi A, Anstett FG, Wells RG. Half-time SPECT myocardial perfusion imaging with attenuation correction. J. Nucl. Med. 50(4), 554-562 (2009).
11. Vanzetto G, Fagret D, Pasqualini R, Mathieu JP, Chossat F, Machecourt J. Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTcN-NOET in healthy volunteers. J. Nucl. Med. 41(1), 141-148 (2000).
12. Giedd KN, Bergmann SR. Fatty acid imaging of the heart. Curr. Cardiol. Rep. 13(2), 121-131 (2011).
13. Dilsizian V, Bateman TM, Bergmann SR et al. Metabolic imaging with b-methyl-p-[(123)I]-iodophenyl-pentadecanoic acid identifies ischemic memory after demand ischemia. Circulation 112(14), 2169-2174 (2005).
14. Kontos MC, Dilsizian V, Weiland F et al. Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: A multicenter trial. J. Am. Coll. Cardiol. 56(4), 290-299 (2010).
15. Inaba Y, Bergmann SR. Diagnostic accuracy of b-methyl-p-[123I]- iodophenyl-pentadecanoic acid (BMIPP) imaging: A meta-analysis. J. Nucl. Cardiol. 15(3), 345-352 (2008).
16. Inaba Y, Bergmann SR. Prognostic value of myocardial metabolic imaging with BMIPP in the spectrum of coronary artery disease: A systematic review. J. Nucl. Cardiol. 17(1), 61-70 (2010).
17. Sharir T, Ben-Haim S, Merzon K et al. High-speed myocardial perfusion imaging initial clinical comparison with conventional dual detector anger camera imaging. JACC Cardiovasc. Imaging 1(2), 156-163 (2008).
18. Esteves FP, Raggi P, Folks RD et al. Novel solid-state-detector dedicated cardiac camera for fast myocardial perfusion imaging: Multicenter comparison with standard dual detector cameras. J. Nucl. Cardiol. 16(6), 927-934 (2009).
19. Garcia EV, Faber TL, Esteves FP. Cardiac dedicated ultrafast SPECT cameras: New designs and clinical implications. J. Nucl. Med. 52(2), 210-217 (2011).
20. Chang HJ, George RT, Schuleri KH et al. Prospective electrocardiogram- gated delayed enhanced multidetector computed tomography accurately quantifies infarct size and reduces radiation exposure. JACC Cardiovasc. Imaging 2(4), 412-420 (2009).
21. Duvall WL, Sweeny JM, Croft LB et al. Comparison of high efficiency CZT SPECT MPI to coronary angiography. J. Nucl. Cardiol. 18(4), 595-604 (2011).
22. Fiechter M, Ghadri JR, Kuest SM et al. Nuclear myocardial perfusion imaging with a novel cadmium-zinc-telluride detector SPECT/CT device: First validation versus invasive coronary angiography. Eur. J. Nucl. Med. Mol. Imaging 38 11), 2025-2030 (2011)
23. Gaemperli O, Schepis T, Valenta I et al. Cardiac image fusion from stand-alone SPECT and CT: Clinical experience. J. Nucl. Med. 48(5), 696-703 (2007).
24. Santana CA, Garcia EV, Faber TL et al. Diagnostic performance of fusion of myocardial perfusion imaging (MPI) and computed tomography coronary angiography. J. Nucl. Cardiol. 16(2), 201-211 (2009).
25. Slomka PJ, Cheng VY, Dey D et al. Quantitative analysis of myocardial perfusion SPECT anatomically guided by coregistered 64-slice coronary CT angiography. J. Nucl. Med. 50(10), 1621-1630 (2009).
26. Rispler S, Keidar Z, Ghersin E et al. Integrated single-photon emission computed tomography and computed tomography coronary angiography for the assessment of hemodynamically significant coronary artery lesions. J. Am. Coll. Cardiol. 49(10), 1059-1067 (2007).
27. Klocke FJ, Baird MG, Lorell BH et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging - executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (ACC/AHA/ASNC Committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). Circulation 108(11), 1404-1418 (2003).
28. Udelson JE, Spiegler EJ. Emergency department perfusion imaging for suspected coronary artery disease: The ERASE chest pain trial. Md. Med. (Suppl.), 90-94 (2001).
29. Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J. Nucl. Cardiol. 11(2), 171-185 (2004).
30. Hachamovitch R, Berman DS, Shaw LJ et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 97(6), 535-543 (1998).
31. Gill JB, Ruddy TD, Newell JB, Finkelstein DM, Strauss HW, Boucher CA. Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N. Engl. J. Med. 317(24), 1486-1489 (1987).
32. Leslie WD, Tully SA, Yogendran MS, Ward LM, Nour KA, Metge CJ. Prognostic value of lung sestamibi uptake in myocardial perfusion imaging of patients with known or suspected coronary artery disease. J. Am. Coll. Cardiol. 45(10), 1676-1682 (2005).
33. Weiss AT, Berman DS, Lew AS et al. Transient ischemic dilation of the left ventricle on stress thallium-201 scintigraphy: A marker of severe and extensive coronary artery disease. J. Am. Coll. Cardiol. 9(4), 752-759 (1987).
34. Mazzanti M, Germano G, Kiat H et al. Identification of severe and extensive coronary artery disease by automatic measurement of transient ischemic dilation of the left ventricle in dual-isotope myocardial perfusion SPECT. J. Am. Coll. Cardiol. 27(7), 1612-1620 (1996).
35. Daniele S, Nappi C, Acampa W et al. Incremental prognostic value of coronary flow reserve assessed with single-photon emission computed tomography. J. Nucl. Cardiol. 18(4), 612-619 (2011).
36. Bateman TM, Heller GV, McGhie AI et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT. J. Nucl. Cardiol. 13(1), 24-33 (2006).
37. Go RT, Marwick TH, Macintyre WJ et al. A prospective comparison of rubidium-82 PET and thallium-201 SPECT myocardial perfusion imaging utilizing a single dipyridamole stress in the diagnosis of coronary artery disease. J. Nucl. Med. 31(12), 1899-1905 (1990).
38. Beanlands RS, Chow BJ, Dick A et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease - executive summary. Can. J. Cardiol. 23(2), 107-119 (2007).
39. Yoshinaga K, Chow BJ, Williams K et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J. Am. Coll. Cardiol. 48(5), 1029-1039 (2006).
40. Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am. J. Cardiol. 80(7), 865-870 (1997).
41. Lertsburapa K, Ahlberg AW, Bateman TM et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J. Nucl. Cardiol. 15(6), 745-753 (2008).
42. Dorbala S, Hachamovitch R, Curillova Z et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. JACC Cardiovasc. Imaging 2(7), 846-854 (2009).
43. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: Role of positron emission tomography. Eur. Heart J. 31(24), 2984-2995 (2010).
44. Madar I, Ravert H, Dipaula A, Du Y, Dannals RF, Becker L. Assessment of severity of coronary artery stenosis in a canine model using the PET agent 18F-fluorobenzyl triphenyl phosphonium: Comparison with 99mTc-tetrofosmin. J. Nucl. Med. 48(6), 1021-1030 (2007).
45. Yu M, Guaraldi MT, Mistry M et al. BMS-747158-02: A novel PET myocardial perfusion imaging agent. J. Nucl. Cardiol. 14(6), 789-798 (2007).
46. Abramson BL, Ruddy TD, Dekemp RA, Laramee LA, Marquis JF, Beanlands RS. Stress perfusion/metabolism imaging: A pilot study for a potential new approach to the diagnosis of coronary disease in women. J. Nucl. Cardiol. 7(3), 205-212 (2000).
47. He ZX, Shi RF, Wu YJ et al. Direct imaging of exercise-induced myocardial ischemia with fluorine-18-labeled deoxyglucose and Tc-99m-sestamibi in coronary artery disease. Circulation 108(10), 1208-1213 (2003).
48. Araujo LI, Mcfalls EO, Lammertsma AA, Jones T, Maseri A. Dipyridamole-induced increased glucose uptake in patients with single-vessel coronary artery disease assessed with PET. J. Nucl. Cardiol. 8(3), 339-346 (2001).
49. Sun KT, Yeatman LA, Buxton DB et al. Simultaneous measurement of myocardial oxygen consumption and blood flow using [1-carbon-11] acetate. J. Nucl. Med. 39(2), 272-280 (1998).
50. Schenker MP, Dorbala S, Hong EC et al. Interrelation of coronary calcification, myocardial ischemia, and outcomes in patients with intermediate likelihood of coronary artery disease: A combined positron emission tomography/computed tomography study. Circulation 117(13), 1693-1700 (2008).
51. Mylonas I, Ziadi MC, Dekemp RA et al. 013 In patients with normal perfusion imaging, is there a relationship between calcium score and myocardial flow reserve? Can. J. Cardiol. 27(5), S66 (2011).
52. Einstein AJ, Johnson LL, Bokhari S et al. Agreement of visual estimation of coronary artery calcium from low-dose CT attenuation correction scans in hybrid PET/CT and SPECT/CT with standard Agatston score. J. Am. Coll. Cardiol. 56(23), 1914-1921 (2010).
53. Kajander S, Joutsiniemi E, Saraste M et al. Cardiac positron emission tomography/ computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation 122(6), 603-613 (2010).
54. Sampson UK, Dorbala S, Limaye A, Kwong R, Di Carli MF. Diagnostic accuracy of rubidium-82 myocardial perfusion imaging with hybrid positron emission tomography/ computed tomography in the detection of coronary artery disease. J. Am. Coll. Cardiol. 49(10), 1052-1058 (2007).
55. Groves AM, Speechly-Dick ME, Kayani I et al. First experience of combined cardiac PET/64-detector CT angiography with invasive angiographic validation. Eur. J. Nucl. Med. Mol. Imaging 36(12), 2027-2033 (2009).
56. Conti M. State of the art and challenges of time-of-flight PET. Phys. Med. 25(1), 1-11 (2009).
57. Parkash R, Dekemp RA, Ruddy TD et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J. Nucl. Cardiol. 11(4), 440-449 (2004).
58. Hajjiri MM, Leavitt MB, Zheng H, Spooner AE, Fischman AJ, Gewirtz H. Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location. JACC Cardiovasc. Imaging 2(6), 751-758 (2009).
59. Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, Dekemp RA. Quantification of myocardial blood flow with 82Rb dynamic PET imaging. Eur. J. Nucl. Med. Mol. Imaging 34(11), 1765-1774 (2007).
60. Camici PG, Rimoldi OE. The clinical value of myocardial blood flow measurement. J. Nucl. Med. 50(7), 1076-1087 (2009).
61. Alexanderson E, Garcia-Rojas L, Jimenez M et al. Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: Assessment by 13N-ammonia positron emission tomography. J. Nucl. Cardiol. 17(6), 1015-1022 (2010).
62. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. JACC Cardiovasc. Imaging 3(6), 623-640 (2010).
63. Brush JE Jr, Cannon RO 3rd, Schenke WH et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N. Engl. J. Med. 319(20), 1302-1307 (1988).
64. Kaufmann PA, Gnecchi-Ruscone T, Di Terlizzi M, Schafers KP, Luscher TF, Camici PG. Coronary heart disease in smokers: Vitamin C restores coronary microcirculatory function. Circulation 102(11), 1233-1238 (2000).
65. Schelbert HR. Coronary circulatory function abnormalities in insulin resistance: Insights from positron emission tomography. J. Am. Coll. Cardiol. 53(Suppl. 5), S3-S8 (2009).
66. Teragawa H, Morita K, Shishido H et al. Impaired myocardial blood flow reserve in subjects with metabolic syndrome analyzed using positron emission tomography and N-13 labeled ammonia. Eur. J. Nucl. Med. Mol. Imaging 37(2), 368-376 (2010).
67. Tamaki N, Yoshinaga K, Naya M. Coronary vasomotor function assessed by positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 37(6), 1213-1224 (2010).
68. Yoshinaga K, Manabe O, Katoh C et al. Quantitative analysis of coronary endothelial function with generator-produced 82Rb PET: Comparison with 15O-labelled water PET. Eur. J. Nucl. Med. Mol. Imaging 37(12), 2233-2241 (2010).
69. Yoshinaga K, Manabe O, Tamaki N. Assessment of coronary endothelial function using PET. J. Nucl. Cardiol. 18(3), 486-500 (2011).
70. Di Carli M, Czernin J, Hoh CK et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 91(7), 1944-1951 (1995).
71. Gould KL. Quantification of coronary artery stenosis in vivo. Circ. Res. 57(3), 341-353 (1985).
72. Beanlands RS, Muzik O, Melon P et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. J. Am. Coll. Cardiol. 26(6), 1465-1475 (1995).
73. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N. Engl. J. Med. 330(25), 1782-1788 (1994).
74. Osborne AD, Moore B, Ross MA, Pitts SR. The feasibility of Rubidium-82 positron emission tomography stress testing in low-risk chest pain protocol patients. Crit. Pathw. Cardiol. 10(1), 41-43 (2011).
75. Nandalur KR, Dwamena BA, Choudhri AF, Nandalur SR, Reddy P, Carlos RC. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: A meta-analysis. Acad. Radiol. 15(4), 444-451 (2008).
76. Shi H, Santana CA, Rivero A et al. Normal values and prospective validation of transient ischaemic dilation index in 82Rb PET myocardial perfusion imaging. Nucl. Med. Commun. 28(11), 859-863 (2007).
77. Dorbala S, Vangala D, Sampson U, Limaye A, Kwong R, Di Carli MF. Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: A 82Rb PET/CT study. J. Nucl. Med. 48(3), 349-358 (2007).
78. Tio RA, Dabeshlim A, Siebelink HM et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J. Nucl. Med. 50(2), 214-219 (2009).
79. Herzog BA, Husmann L, Valenta I et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J. Am. Coll. Cardiol. 54(2), 150-156 (2009).
80. Ziadi MC, Dekemp RA, Williams KA et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J. Am. Coll. Cardiol. 58(7), 740-748 (2011).
81. Fukushima K, Javadi MS, Higuchi T et al. Prediction of short-term cardiovascular events using quantification of global myocardial flow reserve in patients referred for clinical 82Rb PET perfusion imaging. J. Nucl. Med. 52(5), 726-732 (2011).
82. Murthy VL, Naya M, Foster CR et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 124(20), 2215-2224 (2011).
83. Beller GA. Importance of consideration of radiation doses from cardiac imaging procedures and risks of cancer. J. Nucl. Cardiol. 17(1), 1-3 (2010).
84. Einstein AJ, Moser KW, Thompson RC, Cerqueira MD, Henzlova MJ. Radiation dose to patients from cardiac diagnostic imaging. Circulation 116(11), 1290-1305 (2007).
85. Valentin DJ. Chapter 1. Ann. ICRP 28(4), 5-7 (1998).
86. Chen J, Einstein AJ, Fazel R et al. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: A population-based analysis. J. Am. Coll. Cardiol. 56(9), 702-711 (2010).
87. Senthamizhchel Van S, Bravo PE, Lodge MA, Merrill J, Bengel FM, Sgouros G. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J. Nucl. Med. 52(3), 485-491 (2011).
88. Hunter C, Ziadi MC, Etele J, Hill J, Beanlands RS, Dekemp RA. New effective dose estimates for Rubidium-82 based on dynamic PET/CT imaging in humans. Canadian Cardiovascular Society (CCS) CCS185 poster: Imaging: Atherosclerosis and coronary artery disease. Can. J. Cardiol. 26(Suppl.) D(0), 40D-42D (2010).
89. Hendel RC, Berman DS, Di Carli MF et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/ SCMR/SNM 2009 appropriate use criteria for cardiac radionuclide imaging: A report of the American College of Cardiology Foundation appropriate use criteria task force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J. Am. Coll. Cardiol. 53(23), 2201-2229 (2009).
90. Cerqueira MD. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J. Nucl. Cardiol. 17(4), 709-718 (2010).
91. Beller GA. Compliance with appropriate use criteria for cardiac radionuclide imaging. J. Nucl. Cardiol. 17(2), 165-167 (2010).
92. Chang SM, Nabi F, Xu J, Raza U, Mahmarian JJ. Normal stress-only versus standard stress/ rest myocardial perfusion imaging: Similar patient mortality with reduced radiation exposure. J. Am. Coll. Cardiol. 55(3), 221-230 (2010).
93. Bourque JM, Holland BH, Watson DD, Beller GA. Achieving an exercise workload of or = 10 metabolic equivalents predicts a very low risk of inducible ischemia: Does myocardial perfusion imaging have a role? J. Am. Coll. Cardiol. 54(6), 538-545 (2009).
94. Shaw LJ, Mieres JH, Hendel RH et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: Results from the What is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. Circulation 124(11), 1239-1249 (2011).
95. Paterson DI, E O'Meara, Chow BJ, Ukkonen H, Beanlands RS. Recent advances in cardiac imaging for patients with heart failure. Curr. Opin. Cardiol. 26(2), 132-143 (2011).
96. Mielniczuk LM, Beanlands RS. Imaging-guided selection of patients with ischemic heart failure for high risk revascularization improves identification of those with the highest clinical benefit. Circ.Cardiovasc. Imaging 5(2), 262-270; discussion 270 (2012).
97. Fayad ZA, Mani V, Woodward M et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): A randomised clinical trial. Lancet 378(9802), 1547-1559 (2011).
98. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature 451(7181), 953-957 (2008).
99. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: From validation studies to integrated applications. Eur. J. Nucl. Med. Mol. Imaging 36(Suppl. 1), S121-S130 (2009).
100. Sharma J, Roncari C, Giedd KN, Fox JT, Kanei Y. Patients with adenosine-induced ST-segment depressions and normal myocardial perfusion imaging: Cardiac outcomes at 24 months. J. Nucl. Cardiol. 17(5), 874-880 (2010).
101. Williams KA, Schneider CM. Increased stress right ventricular activity on dual isotope perfusion SPECT: A sign of multivessel and/or left main coronary artery disease. J. Am. Coll. Cardiol. 34(2), 420-427 (1999).
102. Abraham A, Kass M, Ruddy TD et al. Right and left ventricular uptake with Rb-82 PET myocardial perfusion imaging: Markers of left main or 3 vessel disease. J. Nucl. Cardiol. 17(1), 52-60 (2010).